Psoricaid for psoriasis, rheumatoid arthritis, crohn's disease, eczema, lupus
Psoricaid contains Phytolacca, Rheum and Scutellaria. These herbs have been used historically in Traditional Chinese Medicine for ‘heat clearing' such as in conditions like constipation due to inflammation. In addition, they have been used traditionally as anti-inflammatory agents and for allergies and dermatitis.
Various in vitro and in vivo studies have shown Psoricaid's effect on inflammatory factors and autoimmunity, particularly on inhibiting cytokines such as tumor necrosis factor alpha, interleukin-1 (IL-1), IL-2, and IL-6 as well as the inflammatory mediators nitric oxide, prostaglandin E2 and leukotrienes. As the following studies will show, Psoricaid is mainly an inhibitor of Th1 type cytokines, which makes it effective for conditions such as psoriasis and rheumatoid arthritis. To some extent, it also inhibits some Th2 type cytokines.
Psoricaid for psoriasis
A study on 300 psoriaisis patients in Chang Hai Hospital in China found that after two months, Psoricaid was effective on 220 patients, which means symptoms associated with psoriasis were eliminated. Improvement was observed in 50 patients while 30 patients experienced no change.
Psoricaid inhibits inflammatory mediators
TNF alpha, IL-1 and IL-6 are not the only targets of Psoricaid. The formula is also able to inhibit the inflammatory mediators prostaglandin E2 (PGE2), nitric oxide (NO) and platelet activating factor (PAF). Levels of these mediators appear to be elevated in certain inflammatory conditions.
Similarly, PGE2 production was reduced following administration of Psoricaid to macrophages. One study shows that, in LPS-stimulated macrophages, the inhibition rates of Psoricain at concentrations of 3, 6, and 12 mmol/l were 13%, 27% and 40%, respectively. This means that Psoricaid is able to block PGE2 production in various states.
Evidence suggests that production of both PGE2 and and NO is influenced by the cytokine IL-1. Therefore, the decrease in PGE2 and NO levels could be attributed to Psoricaid's IL-1 inhibition mechanism.
An in vivo study on mice was performed to compare the effect of Psoricaid and celecoxib (celebrex) on dermatitis and fibrosis induced by radiation. Radiation was applied on the right leg of the mouse to induce the production of inflammatory cyctokines associated with muscle damage. Two days after radiation, changes in several inflammatory cyctokines were measured. After 3 months, fibrosis was assessed.
Results indicate that Psoricaid has a much better effect in reducing damage than Celebrex. The production of the inflammatory cytokines IL-1ß, IL-6, TNFa, IL-1, moncyte chemotactic protein-1 (MCP-1), and vascular endothelial growth factor (VEGF) was much lower in the Psoricaid group than in the Celebrex-treated group. This means that inflammation is more effectively minimised by Psoricaid then Celebrex.
Damage to tissue after radiation can manifest as soft tissue fibrosis. In the same in vivo study, fibrosis was manifested as reduced leg extension. In the Psoricaid group, leg extension was significantly greater than in the control group. This means that Psoricaid was able to increase flexibility even after damage. The Celebrex group, however, showed no significant effect on fibrosis.
There have been a lot of controversy surrounding the use of NSAIDs to alleviate pain and swelling in diseases such as Rheumatoid Arthritis. NSAIDs are inhibitors of cyclooxygenase (COX) enzymes, COX-1 and COX-2. These enzymes stimulate the formation of prostaglandins, which act as inflammatory mediators. That is hwy indirect inhibition of it through the cyclooxygenase pathway is a worthwhile target. Long-term use of NSAIDs can cause gastrointestinal (GI) bleeding. Because prostaglandins have a protective effect on GI mucosa, inhibiting it directly though the COX-1 pathway removes this GI protection, resulting in increased risk of GI perforation, ulceration, and bleeding. Scientists have found a way to circumvent this side effect through COX-2 inhibitors. However, COX-2 inhibitors carry an increased risk of cardiovascular problems and GI side effects and many have been taken off the market. Psoricaid does not carry GI bleeding risk.
Due to the side effects associated with conventional anti-inflammatory treatments like NSAIDs, inflammatory disease sufferers are turning to other modes of treatment: cytokine-based therapy.
Psoricaid For Psoriasis, Eczema, Dermatitis
Psoricaid is an herbal formula that inhibits inflammatory cytokines associated with conditions such as psoriasis, eczema and dermatitis. It contains phytolacca, Rheum and Scutellaria. These herbs have been used historically in Traditional Chinese Medicine for “heat clearing” such as in condtions like constipation due to inflammation. In addition, they have been used traditionally as anti-inflammatory agents and for allergies and dermatitis.
In chapter 5, various in vitro and in vivo studies were present to so Psoricaid's effect on inflammatory factors and autoimmunity, particularly on inhibiting cytokines such as tumor necrosis factor alpha (TNFa), interleukin-1 (IL-1), IL-2 and IL-6 as well as the inflammatory mediators nitric oxide, prostaglandin E2 and leukotrienes. These cytokines are overexpressed in various autoimmune conditions. Psoriatic tissue, for example, is known to have an overexpression of TNFa. Inhibition of cytokines is one of the more effective methods of reducing severity and frequency of symptoms of autoimmune conditions.
Psoricaid inhibits inflammatory mediators and inflammation
Both in vitro and in vivo studies show that psoricaid inhibits TNFa, IL-1, and IL-6 in a dosage-dependant manner. These results signify that Psoricaid does have a therapeutic application in psoriasis and other diseases that overexpress these cytokines.
Psoricaid does not carry risk of GI bleeding
Psoricaid's inhibition of various inflammatory mediators (and not through COX-2 inhibition) makes it a potentially more effective anti-inflammator agent. It does not carry the risk of GI bleeding as COX-2 inhibitors do. There is evidence that Rheum palmatum, on of Psoricaid's ingredients, reduces GI bleeding. In 400 cases of upper GI bleeding, administration of 3 grams of Rheum for 6 to 12 hours was found to be effective in about 95% of the cases. In another study, Rheum was compared with conventional medicine in 60 patients. Half of the patients were given Rheum and the other half given conventional treatment. The disappearance of occult blood in the Rheum group was 5 days earlier than those in the conventional medicine group.
Additional Details of Psoricaid 120 Capsules - Chi's Enterprise
Cost Per Serving: $0.67
Weight:
0.48 lbs
SKU:
003-05-012-00
Additional notes:
Keep bottle tightly closed. Store in a cool, dry place.
Brand:
Chi's Enterprise
Delivery type:
Vegetarian Capsule
Contraindications :
Consult your physician before use
Special instructions:
Keep bottle tightly closed. Store in a cool, dry place.
MPN:
2516
UPC:
704889389699
Return Policy:
45 Day Money Back Guarantee!
Made In:
USA
